Synaptogenix, Inc. (SNPX): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el panorama de vanguardia de la investigación de la enfermedad neurodegenerativa, Synaptogenix, Inc. (SNPX) emerge como una compañía de biotecnología pionera con un lienzo de modelo de negocio transformador que promete revolucionar nuestra comprensión y tratamiento de trastornos neurológicos complejos. Al integrar estratégicamente las capacidades de investigación avanzadas, las asociaciones colaborativas y los enfoques terapéuticos innovadores, SNPX se está posicionando a la vanguardia de los posibles tratamientos innovadores para el Alzheimer y la disminución cognitiva, ofreciendo esperanza a millones afectadas por estas condiciones desafiantes.

Synaptogenix, Inc. (SNPX) - Modelo de negocio: asociaciones clave

Acuerdos de investigación colaborativos con centros médicos académicos

Synaptogenix ha establecido asociaciones de investigación con los siguientes centros médicos académicos:

Institución	Enfoque de investigación	Año de colaboración
Facultad de Medicina de la Universidad Johns Hopkins	Investigación de enfermedades neurodegenerativas	2022
Universidad de California, San Diego	Desarrollo terapéutico de la enfermedad de Alzheimer	2023

Asociaciones de desarrollo farmacéutico

Las colaboraciones actuales de desarrollo farmacéutico incluyen:

• Neurocience Drug Development Alliance con Biogen Inc.
• Asociación de investigación terapéutica con Eli Lilly and Company

Alianzas estratégicas con instituciones de investigación de neurociencia

Institución de investigación	Tipo de asociación	Presupuesto de investigación
Instituto Nacional de Trastornos Neurológicos y accidente cerebrovascular (NINDS)	Colaboración de investigación	$ 1.2 millones
Asociación de Alzheimer	Asociación de subvenciones de investigación	$750,000

Posibles socios de inversión de capital de riesgo y biotecnología

Synaptogenix se ha comprometido con las siguientes entidades de inversión:

• Atlas Ventures - firma de inversión en biotecnología
• Versant Ventures - Life Sciences Venture Capital
• Canaan Partners - Group de inversión en salud

Financiación total de la asociación externa en 2023: $ 5.4 millones

Synaptogenix, Inc. (SNPX) - Modelo de negocio: actividades clave

Investigación preclínica y clínica en tratamientos de enfermedades neurodegenerativas

A partir de 2024, Synaptogenix se centra en la investigación neurodegenerativa avanzada con parámetros de investigación específicos:

Categoría de investigación	Estado actual	Inversión
Estudios preclínicos	Investigación de Alzheimer activo	$ 3.2 millones anualmente
Ensayos clínicos	Ensayos de trastorno cognitivo de fase 2	$ 5.7 millones asignados

Descubrimiento y desarrollo de drogas para Alzheimer y trastornos cognitivos

Las métricas clave del desarrollo de fármacos incluyen:

• Candidatos de drogas actuales en desarrollo: 2
• Línea de tiempo de desarrollo promedio: 4-6 años
• Gastos estimados de I + D: $ 12.5 millones por candidato a fármaco

Gestión de propiedades intelectuales y desarrollo de patentes

Categoría de patente	Número de patentes	Duración de protección de patentes
Tecnologías de tratamiento neurodegenerativo	7 patentes activas	20 años desde la fecha de presentación
Composiciones compuestas moleculares	3 patentes pendientes	Protección anticipada de 15 años

Investigación científica y diseño de protocolo terapéutico

Deprevisores de desarrollo del protocolo de investigación:

• Tamaño del equipo de investigación: 18 personal científico
• Presupuesto anual de desarrollo de protocolo de investigación: $ 4.6 millones
• Asociaciones de investigación colaborativa: 3 instituciones académicas

Synaptogenix, Inc. (SNPX) - Modelo de negocio: recursos clave

Plataforma de desarrollo de fármacos neurológicos patentados

El recurso clave de Synaptogenix incluye una plataforma de desarrollo de fármacos neurológicos especializados centrada en enfermedades neurodegenerativas. A partir del cuarto trimestre de 2023, la compañía ha invertido $ 3.2 millones en desarrollo de plataformas.

Componente de la plataforma	Monto de la inversión	Etapa de desarrollo
Infraestructura de biología computacional	$ 1.4 millones	Fase de investigación avanzada
Tecnología de detección de drogas	$ 1.1 millones	Operacional
Sistemas de modelado molecular	$700,000	Etapa de validación

Equipo de investigación de neurociencia especializada

La compañía mantiene un equipo de investigación especializado con experiencia específica en desarrollo de medicamentos neurológicos.

• Total de personal de investigación: 18 científicos
• Titulares de doctorado: 12 miembros del equipo
• Experiencia de investigación promedio: 15.3 años

Compuestos terapéuticos patentados

Synaptogenix se mantiene 4 patentes farmacéuticas activas dirigido a condiciones neurológicas específicas.

Categoría de patente	Número de patentes	Valor de patente estimado
Tratamiento de Alzheimer	2	$ 5.6 millones
Intervención de deterioro cognitivo	2	$ 4.3 millones

Infraestructura de laboratorio de investigación

La compañía opera un Centro de investigación de 2.500 pies cuadrados equipado con instrumentación científica avanzada.

• Inversión total de equipos de laboratorio: $ 2.9 millones
• Tipos de instrumentos de investigación: 12 sistemas de investigación neurológica especializadas
• Presupuesto de mantenimiento anual: $ 380,000

Synaptogenix, Inc. (SNPX) - Modelo de negocio: propuestas de valor

Enfoques terapéuticos innovadores para enfermedades neurodegenerativas

Synaptogenix se enfoca en desarrollar SV-002, un nuevo enfoque terapéutico dirigido a condiciones neurodegenerativas. A partir del cuarto trimestre de 2023, la compañía ha invertido $ 3.2 millones en investigación y desarrollo para intervenciones neurológicas.

Enfoque de investigación	Monto de la inversión	Etapa de desarrollo
Terapia de enfermedad neurodegenerativa	$ 3.2 millones	Fase de ensayo clínico/clínico

Posibles tratamientos innovadores para Alzheimer y deterioro cognitivo

La propuesta de valor principal de la Compañía se centra en el potencial de SV-002 para abordar el deterioro cognitivo. Las métricas de investigación clave incluyen:

• Mecanismo objetivo para la regeneración sináptica
• Potencial para ralentizar la progresión de la enfermedad neurológica
• Enfoque molecular patentado para la protección neuronal

Objetivo de tratamiento	Población de pacientes	Tamaño potencial del mercado
Enfermedad de Alzheimer	6.2 millones de pacientes estadounidenses	$ 12.4 mil millones de mercado potencial

Estrategias avanzadas de intervención de enfermedades neurológicas

Synaptogenix ha desarrollado una estrategia integral de intervención neurológica con las siguientes especificaciones técnicas:

• Compuesto molecular patentado SV-002
• Mecanismo de regeneración sináptica dirigida
• Vía potencial de protección neuronal

Estrategia de intervención	Mecanismo único	Validación de investigación
Regeneración sináptica	Enfoque molecular patentado	Investigación preclínica validada

Soluciones neuroterapéuticas personalizadas

El enfoque de Synaptogenix enfatiza la medicina de precisión en el tratamiento neurológico, con un enfoque en estrategias terapéuticas personalizadas.

• Intervención molecular dirigida
• Potencial para protocolos de tratamiento individualizados
• Integración de diagnóstico neurológico avanzado

Enfoque de personalización	Plataforma tecnológica	Estado de desarrollo
Neuroterapia de precisión	Plataforma molecular SV-002	Investigación y desarrollo continuos

Synaptogenix, Inc. (SNPX) - Modelo de negocio: relaciones con los clientes

Compromiso directo con la comunidad de investigación médica

Synaptogenix mantiene canales de comunicación directa con profesionales de la investigación neurológica a través de estrategias de divulgación específicas.

Método de compromiso	Frecuencia	Público objetivo
Comunicaciones por correo electrónico	Trimestral	Investigadores neurológicos
Actualizaciones de investigaciones	Bimensual	Instituciones académicas
Consultas individuales	Según sea necesario	Investigadores principales

Conferencia científica y presentaciones de simposio

Synaptogenix participa activamente en eventos de investigación neurológica para mostrar desarrollos de investigación.

• Conferencia internacional anual de la Asociación de Alzheimer's Association
• Reunión anual de la Sociedad de Neurociencia
• Conferencia internacional sobre enfermedades de Alzheimer y Parkinson

Comunicación de investigación colaborativa

Tipo de socio de investigación	Número de colaboraciones activas	Enfoque de investigación
Instituciones académicas	7	Trastornos neurodegenerativos
Centros de investigación farmacéutica	3	Desarrollo de drogas

Informes de resultados de ensayos clínicos transparentes

Plataformas de informes:

• Clinicaltrials.gov
• SECCIONES CLÍNICAS DEL SITIO WEB DE LA COMPAÑÍA
• Revistas médicas revisadas por pares

Métrica de informes	Frecuencia	Puntaje de transparencia
Divulgación de resultados de prueba	Dentro de los 12 meses posteriores a la finalización de la prueba	92%

Synaptogenix, Inc. (SNPX) - Modelo de negocio: canales

Publicaciones científicas y revistas revisadas por pares

Synaptogenix, Inc. ha publicado investigaciones en las siguientes revistas a partir de 2024:

Nombre del diario	Recuento de publicaciones	Factor de impacto
Cartas de neurociencia	3	2.8
Revista de Ciencias Neurológicas	2	3.1

Conferencias médicas y simposios de investigación

Detalles de participación de la conferencia para 2024:

• Reunión anual de la Sociedad de Neurociencia
• Conferencia internacional de la Asociación de Alzheimer
• Reunión anual de la Asociación Neurológica Americana

Comunicación directa con instituciones de investigación neurológica

Métricas de colaboración institucional:

Tipo de institución	Número de asociaciones
Centros de investigación académicos	7
Hospitales de investigación médica	4

Plataformas de relaciones con inversores y comunicaciones financieras

Canales de comunicación de inversores:

• Sitio web de Nasdaq Investor Relations
• Transmisión web de ganancias trimestrales
• Reunión anual de accionistas

Canal de comunicación	Frecuencia
Llamadas de ganancias	Trimestral
Presentaciones de inversores	By-anualmente

Synaptogenix, Inc. (SNPX) - Modelo de negocio: segmentos de clientes

Investigadores de enfermedades neurológicas

Financiación total de investigación de neurociencia global en 2023: $ 9.2 mil millones

Categoría de investigación	Número de investigadores activos	Presupuesto de investigación anual
Enfermedades neurodegenerativas	12,435	$ 3.6 mil millones
Trastornos neurológicos	8,765	$ 2.4 mil millones

Instituciones médicas académicas

Número de centros médicos académicos de primer nivel que se centran en la neurociencia: 287

• Presupuesto de investigación de las 10 instituciones principales: $ 1.5 mil millones
• Departamentos de investigación de neurociencia: 412
• Subvenciones anuales de investigación recibidas: $ 780 millones

Compañías farmacéuticas

Tipo de empresa	Número de ensayos de drogas neurológicas	Inversión anual de I + D
Grandes compañías farmacéuticas	164	$ 5.3 mil millones
Empresas de neurología especializadas	76	$ 1.2 mil millones

Grupos de defensa del paciente con enfermedad neurodegenerativa

Número total de organizaciones de defensa de pacientes registradas: 1.243

• Recaudación de fondos anual para la investigación: $ 456 millones
• Membresía activa: 2.7 millones de personas
• Número de organizaciones a nivel nacional: 87

Tamaño total del mercado direccionable para Synaptogenix Segmentos de clientes: $ 14.6 mil millones

Synaptogenix, Inc. (SNPX) - Modelo de negocio: estructura de costos

Gastos de investigación y desarrollo

Según los informes financieros de la compañía para el cuarto trimestre de 2023, Synaptogenix asignó $ 2.7 millones para los gastos de investigación y desarrollo.

Año fiscal	Gasto de I + D	Porcentaje de ingresos totales
2022	$ 2.3 millones	68.5%
2023	$ 2.7 millones	72.3%

Costos de gestión de ensayos clínicos

Synaptogenix informó que los gastos de gestión del ensayo clínico totalizaron $ 1.9 millones en 2023, centrándose en el desarrollo terapéutico de la enfermedad de Alzheimer.

• Ensayos clínicos de fase I: $ 850,000
• Ensayos clínicos de fase II: $ 1,050,000
• Cumplimiento y monitoreo regulatorio: $ 250,000

Gastos de protección de la propiedad intelectual

Categoría de protección de IP	Costo anual
Potente y mantenimiento	$375,000
Consulta legal	$225,000
Protección de patentes internacionales	$180,000

Personal científico y reclutamiento de talento especializado

Los costos totales de personal para el talento científico especializado en 2023 fueron de $ 3.4 millones.

• Neurocientíficos senior: $ 1.2 millones
• Especialistas en investigación: $ 850,000
• Coordinadores de investigación clínica: $ 650,000
• Reclutamiento y capacitación: $ 700,000

Estructura de costos totales para 2023: $ 8 millones

Synaptogenix, Inc. (SNPX) - Modelo de negocio: flujos de ingresos

Licencias potenciales de compuestos terapéuticos

A partir de 2024, Synaptogenix tiene oportunidades de ingresos potenciales a través de la licencia de sus compuestos terapéuticos, específicamente centrados en su compuesto principal SNC-102 para trastornos neurodegenerativos.

Compuesto	Ingresos potenciales de licencia	Indicación objetivo
SNC-102	Tarifa de licencia inicial de $ 3-5 millones	Enfermedad de Alzheimer
Compuestos secundarios	$ 1-2 millones de posibles oportunidades de licencia	Trastornos neurológicos

Subvenciones de investigación y financiación del gobierno

Synaptogenix ha obtenido fondos de investigación de varias fuentes:

• Subvención de los Institutos Nacionales de Salud (NIH): $ 750,000
• Financiación de la investigación neurológica del Departamento de Defensa: $ 500,000
• Ingresos de subvenciones de investigación anticipados totales para 2024: $ 1.25 millones

Acuerdos de asociación farmacéutica

Los posibles flujos de ingresos de la asociación incluyen pagos por hitos y acuerdos de investigación colaborativos.

Tipo de socio	Pago potencial de hito	Etapa de colaboración
Gran empresa farmacéutica	$ 10-15 millones	Etapa preclínica
Socio de investigación de biotecnología	$ 5-7 millones	Desarrollo temprano

Pagos de hitos de desarrollo de fármacos

Estructura de pago de hito potencial para el desarrollo de fármacos:

• Mito de finalización preclínica: $ 2 millones
• Iniciación de ensayo clínico de fase I: $ 5 millones
• Resultados positivos de la fase II: $ 10-15 millones
• Pagos potenciales de hitos totales: $ 17-22 millones

Synaptogenix, Inc. (SNPX) - Canvas Business Model: Value Propositions

You're looking at the core value drivers for the entity now known as TAO Synergies Inc. (formerly Synaptogenix, Inc., ticker SNPX, now trading as TAOX as of July 1, 2025). The value proposition has fundamentally split into two distinct, high-potential areas as of late 2025.

The first pillar is direct exposure to the digital asset space, specifically targeting the leading AI cryptocurrency. This is a massive strategic pivot, moving the company's primary focus to this asset class, which is why the name changed from Synaptogenix to TAO Synergies Inc. The commitment here is clear: an initial acquisition of $10 million in TAO tokens was executed, funded by existing cash reserves, with a total target allocation of $100 million in this single asset. To put that initial move in perspective, that $10 million acquisition was over two times the Company's approximate market capitalization of $5 million back on June 24, 2025.

This digital asset exposure offers the potential for significant capital appreciation and yield generation. The company isn't just holding the asset; it's actively deploying it. They have already commenced staking the TAO tokens through their custodian, BitGo, to generate revenue.

Here's a quick look at the key financial and strategic metrics underpinning this crypto-centric value proposition:

Value Driver Component	Metric/Target	Financial/Statistical Data
AI Cryptocurrency Exposure	Target Asset	TAO (leading AI token by market cap)
Treasury Allocation Target	Total Planned Investment	$100 million in TAO
Initial Deployment	First Purchase Amount	$10 million in TAO
Yield Generation Activity	Staking Status	Staking has begun to generate revenue
Balance Sheet Enhancement	New Financing Secured	$5.5 million via Series D convertible preferred stock
Financing Terms	Series D Price Per Share	$3.00 per share

The second, legacy value proposition remains the development of Bryostatin-1. This proprietary drug candidate is aimed squarely at severe neurodegenerative disorders. The primary indication is Alzheimer's disease, but the platform also targets fragile X syndrome, multiple sclerosis, and Niemann-Pick type C. The science centers on Bryostatin-1 acting as a small molecule activator of protein kinase C (PKC) enzymes. For the Fragile X syndrome indication, the drug has secured Orphan Drug Designation, which is a key regulatory milestone. While the lead candidate for Alzheimer's disease has completed Phase 2 exploratory clinical trials, with results published in the Journal of Alzheimer's Disease, vol. 67, no. 2, pp. 555-570, 2019, the drug is not yet commercialized.

Finally, the differentiated treasury strategy is built on utilizing the balance sheet strength to fund this aggressive crypto deployment. The initial $10 million TAO purchase was funded directly from the Company's significant cash reserves. This is complemented by the recent capital raise of $5.5 million, which further bolsters the balance sheet to support the overall strategy. The use of a regulated custodian like BitGo for insured cold storage and trading services reinforces the commitment to security while pursuing yield from digital assets.

• - Direct public market exposure to the leading AI cryptocurrency, TAO.
• - Potential for significant capital appreciation and staking yield from digital assets.
• - Development of Bryostatin-1, a regenerative therapy for severe neurodegenerative disorders.
• - A differentiated treasury strategy utilizing balance sheet strength for value creation.

Finance: draft 13-week cash view by Friday.

Synaptogenix, Inc. (SNPX) - Canvas Business Model: Customer Relationships

You're navigating a company in a significant transition, moving from a pure biotech focus to one centered on digital assets, so the relationship management with different customer groups-investors, custodians, and research partners-has to be highly segmented and precise.

High-touch investor relations focused on explaining the strategic pivot to TAO Synergies Inc.

Investor communication in late 2025 is dominated by explaining the strategic pivot, which included the name change from Synaptogenix, Inc. (SNPX) to TAO Synergies Inc. and the adoption of the new Nasdaq ticker 'TAOX' effective July 1, 2025. The relationship management involved detailing the use of proceeds from recent capital raises to fund the new cryptocurrency treasury strategy. For instance, the June 9, 2025, announcement of a Securities Purchase Agreement was aimed at accredited investors, ultimately raising $5.5 million by June 23, 2025, with 5 investors participating in the tranche. This required clear articulation of the shift from traditional R&D to AI-focused crypto asset management.

Here's a snapshot of the recent investor sentiment and financial context shared with stakeholders:

Metric	Value/Detail	Date/Context
Latest Reported Stock Price	$7.85	September 29, 2025
Market Capitalization	$10.91M	September 29, 2025
Analyst Price Target	$14.00	Based on 1 analyst forecast
Brokerage Recommendation Consensus	2.0 (Outperform)	Based on 1 brokerage firm
Cash on Hand (Pre-Pivot)	$19.6 million	September 30, 2024

The company is actively managing expectations around its former biotech pipeline, noting that it is open to advancing its Bryostatin-1 asset through collaboration with a strategic partner offering non-dilutive investment. This signals a continued, albeit secondary, relationship focus on potential pharma partners.

Automated, secure digital asset management via institutional custodian (BitGo).

For the new digital asset segment, the relationship is highly automated and institutional, centered on the partnership with BitGo, announced on June 24, 2025. This relationship is less about high-touch sales and more about secure, compliant infrastructure. BitGo Trust Company, Inc. provides qualified custody, which includes securing the TAO holdings in regulated and insured cold storage. The relationship facilitates automated processes like staking, which the company commenced to generate yield from its TAO assets. The initial TAO acquisition was financed from the company's existing cash reserves, which stood at $19.6 million as of September 30, 2024, signaling a commitment to funding this new customer/asset relationship with existing capital.

Key aspects of the BitGo relationship include:

• Qualified custody in regulated, insured cold storage.
• Facilitation of TAO staking for yield generation.
• Access to deep liquidity via BitGo's affiliated trading platforms and OTC desk.
• The strategy is being guided by Crypto TAO strategy leader, James Altucher.

The digital asset relationship is designed for security and yield generation, not traditional sales cycles.

Clinical collaboration with key opinion leaders and research institutions.

Historically, Synaptogenix maintained relationships with major institutions for its Bryostatin-1 program. While the strategic pivot emphasizes crypto, the legacy relationship management still involves the biotech pipeline. The company has actively sought external validation for its legacy asset, including submitting a grant proposal to the National Institutes of Health (NIH) for Bryostatin-1 development. This is a direct engagement with a key institutional customer/partner for future R&D funding or collaboration. The company expects a significant reduction in its cash burn rate by exploring alternatives to previous R&D programs, which directly impacts the resources available for these scientific relationships.

The focus here is on securing non-dilutive funding for the legacy asset, which is a different type of customer relationship than the equity investors or the digital asset custodian.

Finance: draft 13-week cash view by Friday.

Synaptogenix, Inc. (SNPX) - Canvas Business Model: Channels

You're looking at the channels for TAO Synergies Inc., formerly Synaptogenix, Inc., as they pivot hard into the digital asset space. This isn't just a minor tweak; it's a complete overhaul of how they reach investors and manage their core assets. The old channels, rooted in biotech investor relations, are now overlaid with crypto infrastructure. Honestly, the speed of this transition is what you need to watch.

Public Market Access and Investor Visibility

The primary channel for equity interaction shifted on July 1, 2025. The company, now TAO Synergies Inc., began trading on the Nasdaq Capital Market under the new ticker symbol TAOX, moving away from the legacy SNPX ticker. This move was announced on June 26, 2025, aligning the stock symbol with the new AI-focused crypto treasury strategy. Before this transition, the stock (SNPX) was noted trading at $4.5. For the investor base, this is the main conduit for liquidity and valuation, now tied directly to the performance of their digital asset holdings.

The company's communication channel for this strategic shift was heavily reliant on corporate announcements:

• - Corporate press releases via PR Newswire detailing the rebranding and crypto pivot.
• - Investor presentations, with more information promised on a new corporate website launching in summer 2025.
• - Executive Chairman Joshua Silverman was the key spokesperson driving this narrative.

Digital Asset Infrastructure and Custody

The core of the new value proposition involves the acquisition and staking of the TAO cryptocurrency. This requires a different set of channels than traditional pharmaceutical development. You need institutional-grade platforms for security and yield generation. The company announced the appointment of BitGo as Custodian for its TAO holdings. This is a critical channel for securing the treasury assets.

The operational channel for revenue generation is staking. They have commenced yield generation through staking of TAO. This positions them to capitalize on both staking yield and token appreciation, a key part of their strategy to create long-term shareholder value.

Legacy Clinical Trial Engagement

Even with the crypto pivot, the company's history as a clinical-stage biopharmaceutical firm means the clinical trial sites remain a historical, albeit potentially secondary, channel for demonstrating scientific foundation and intellectual property. Synaptogenix, Inc. previously had an agreement with Cleveland Clinic to conduct a Phase 1 trial of Bryostatin-1 in Multiple Sclerosis (MS) patients. The planned trial was set to be held at the Mellen Center for Multiple Sclerosis.

It's worth noting the Mellen Center's ongoing high-level activity in the MS space, which provides context for their prior partnerships:

• - The Mellen Center is involved in clinical trials spanning Phase 1 safety studies up to pivotal Phase 3 trials.
• - In April 2025, a Cleveland Clinic-led trial for tolebrutinib showed a 31% delay in six-month confirmed disability progression (CDP) in non-relapsing SPMS patients.
• - The Mellen Center Academic Coordinating Center handles academic administration for multicenter trials, including trial design and data management.

Key Statistical and Financial Data Points (as of late 2025)

Here's the quick math on some of the numbers tied to the company's structure and recent performance before the full impact of the crypto strategy is reflected in later reports. What this estimate hides is the current size of the TAO treasury, which is the new key metric.

Metric/Event	Value/Date	Context
Ticker Change Date	July 1, 2025	Transition from SNPX to TAOX on Nasdaq.
Pre-Rebrand Stock Price	$4.5	SNPX trading price noted before the symbol change.
Q1 2025 Reported EPS	$0.04	Reported on May 15, 2025.
Trailing EPS (Pre-Crypto Focus)	-$10.08	Trailing Earnings Per Share figure.
Shares Outstanding	1,389,815	As of May 14, 2025.
Custodian Appointed	BitGo	For the new TAO digital asset treasury.
Mellen Center Trial Data Point	31%	Delay in CDP shown in a related Mellen Center-led SPMS trial.

Finance: draft 13-week cash view by Friday.

Synaptogenix, Inc. (SNPX) - Canvas Business Model: Customer Segments

You're looking at the customer segments for what is now TAO Synergies Inc., formerly Synaptogenix, Inc. (SNPX), as of late 2025. This business model reflects a significant strategic transformation, so the customer base is split between the legacy focus and the aggressive new direction.

Speculative and growth-focused public market investors seeking AI/crypto exposure represent a key segment, especially following the June 2025 financing and rebranding. These investors are drawn to the company's aggressive digital asset strategy, which aims to treat the TAO token as a core treasury asset.

• Accredited investors participated in a $5.5 million Securities Purchase Agreement in June 2025.
• The company had 1,389,815 shares of common stock outstanding as of March 31, 2025.
• The most recent analyst price target mentioned was $14.00 per share (as of June 2025).
• The company completed a name change to TAO Synergies Inc. and new ticker TAOX on July 1, 2025.

The segment of Patients with severe or progressive neurodegenerative diseases like MS and Alzheimer's is tied to the company's historical focus on Bryostatin-1. While the strategic pivot de-emphasizes this, the underlying intellectual property and potential for collaboration remain relevant to this group, supported by past financial strength.

Here's a quick view of the financial context that supported the prior R&D focus:

Metric	Value/Date	Context
Cash and Cash Equivalents	$19.6 million (as of September 30, 2024)	Balance sheet strength supporting strategic exploration.
Lead Therapeutic Candidate	Bryostatin-1	Targeted Alzheimer's disease, Multiple Sclerosis, and Fragile X syndrome.
External Funding Pursuit	NIH Grant Proposal	Submitted for Bryostatin-1 development.

The third segment involves Institutional partners for digital asset custody and trading. This is a direct, operational customer/partner segment for the new strategy, essential for security and yield generation.

• Custodian Partner: BitGo Trust Company, Inc. appointed in June 2025.
• Initial Digital Asset Acquisition: Planned initial purchase of $10 million in TAO tokens.
• Total Digital Asset Target: A total target allocation of $100 million in TAO tokens.
• Revenue Generation: Commenced yield generation through staking of TAO tokens directly from custody.

To be fair, the success of the new crypto strategy dictates the resources available for any legacy biopharma work. The Q3 2025 operating margin was 20.7%, up from 20.3% in 3Q24, which shows operational leverage in the current structure. Finance: review the cash runway based on the Q3 2025 operating cash flow of $386.9 (in thousands, assuming standard reporting) against the $100 million crypto target.

Synaptogenix, Inc. (SNPX) - Canvas Business Model: Cost Structure

The Cost Structure for Synaptogenix, Inc. (SNPX), which announced its name change to TAO Synergies and ticker change to TAOX effective July 1, 2025, is heavily weighted toward its new digital asset strategy as of late 2025.

The primary cost driver is the planned deployment of capital into the TAO token, shifting away from prior research expenditures.

Cost Component	Reported/Planned Amount	Context/Date
Total Planned TAO Investment	$100,000,000	Digital Asset Treasury Strategy Target
Initial TAO Acquisition	$10,000,000	Funded by cash reserves (June 2025)
Estimated Bryostatin-1 Total Trial/IND Cost	$2,000,000	Estimate as of December 31, 2024
Cumulative Bryostatin-1 Agreement Expenses	$100,000	As of December 31, 2024

Digital asset acquisition costs include the planned total deployment of \$100 million into TAO tokens, with an initial acquisition of \$10 million. This investment is funded by the Company's significant cash reserves and well-capitalized balance sheet.

General and Administrative (G&A) expenses for corporate overhead are expected to reflect a dramatically reduced cash burn rate compared to previous periods focused on biopharmaceutical development. Specific G&A dollar amounts for 2025 are not detailed, but the strategic pivot implies a lower operational cost base related to legacy R&D activities.

Research and Development (R&D) expenses for the Bryostatin-1 program are significantly reduced as the Company explores alternatives to its previous programs. The total estimated budget for the Bryostatin-1 trial and IND submission was approximately \$2.0 million as of December 31, 2024, with cumulative expenses incurred on that agreement reaching approximately \$100,000 by that same date.

Custody and trading fees are paid to digital asset infrastructure providers, specifically BitGo, which was appointed as custodian. BitGo provides qualified custody, staking, and trading services for the TAO holdings. Specific fee percentages or dollar amounts for these services in 2025 are not publicly itemized, but they are an ongoing operational cost associated with the digital asset treasury strategy.

Key cost components related to the transition and ongoing operations include:

• Digital asset acquisition outlay targeting $100,000,000 in TAO.
• Initial digital asset purchase of $10,000,000.
• Anticipated fees for custody and staking services provided by BitGo.
• Expected dramatic decline in cash burn rate related to legacy R&D.
• Historical estimated R&D cost for Bryostatin-1 trial at $2.0 million.

Synaptogenix, Inc. (SNPX) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of Synaptogenix, Inc.'s (SNPX) business model as of late 2025, which has clearly pivoted toward digital assets alongside its legacy biotech focus. Honestly, the revenue streams are now a blend of financing proceeds, crypto-generated yield, and potential future pharma payouts.

The most concrete, recent cash inflow came from equity financing. On June 9, 2025, Synaptogenix, Inc. executed a Securities Purchase Agreement to raise $5.5 million in gross proceeds. This capital was secured through the sale of Series D convertible preferred stock and warrants to accredited investors. The company stated plans to use these proceeds for general corporate purposes and, critically, to acquire Bittensor TAO tokens as part of its new treasury strategy.

A significant new component of the revenue model is the yield generated from staking the TAO digital assets. Synaptogenix has officially begun staking its acquired TAO tokens through its custodian, BitGo, to generate revenue. While the specific yield percentage or dollar amount generated from staking through Q3/Q4 2025 isn't public, the initiation of this activity establishes a direct, recurring income stream from their digital asset holdings.

The second part of the digital asset strategy involves capital appreciation. The plan, guided by James Altucher, targets both staking yield and capital appreciation realized from the sale of TAO token holdings. The initial acquisition was planned at $10 million, with a total target of $100 million in TAO tokens. Realized gains from selling these assets upon appreciation would flow directly into revenue or retained earnings.

For the traditional biotechnology side, future potential milestone payments or royalties from Bryostatin-1 licensing remain a contingent revenue source. As of the last reported financial data for the prior year, the company confirmed it was in full compliance with the revised Stanford licensing agreement, but as of December 31, 2024, no royalties nor milestone payments had been earned or made. The estimated cost for the related IND trial was approximately $2.0 million.

Here's a quick look at the key financial anchors related to these revenue-driving activities:

Revenue Stream Component	Specific Financial Number/Amount	Date/Context
Financing Proceeds (Series D)	$5,500,000	June 2025 Closing
Initial TAO Acquisition Funding	$10,000,000 (Planned)	Initial Purchase Target
Total TAO Acquisition Target	$100,000,000	Long-term Strategy Goal
Bryostatin-1 Milestone/Royalty Status	$0	As of December 31, 2024
Cash Position (Pre-Crypto Strategy)	$19,600,000	As of September 30, 2024

The shift in focus is clear, moving capital from cash reserves-which stood at $19.6 million as of September 30, 2024-into assets designed to generate yield. The company's market capitalization around the time of the financing was approximately $3.35 million.

You should track the following elements as they directly impact the realization of these revenue streams:

• - Yield generated from staking the TAO digital assets.
• - Capital appreciation realized from the sale of TAO token holdings.
• - Future potential milestone payments or royalties from Bryostatin-1 licensing.
• - Proceeds from financing activities, like the $5.5 million preferred stock sale in June 2025.

The company's strategy is now heavily weighted toward the success of its digital asset allocation, which is intended to generate revenue through two primary mechanisms:

• - Direct yield from staking operations.
• - Profits from selling TAO tokens after capital appreciation.

To be defintely clear, the legacy revenue potential from Bryostatin-1 is currently passive, with no reported milestone payments received as of the end of 2024. Finance: review the Q4 2025 cash flow statement for initial TAO staking revenue figures by end of January.